Skip to main content

Advertisement

Table 3 Univariate and multivariate analyses of prognostic markers for PFS

From: Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

  Univariate analysis (p-value) Multivariate analysis (p-value)
Afatinib vs. erlotinib 0.97 ND
Age ≤70 years 0.008 0.006
Sex 0.79 ND
Smoking status 0.25 ND
Histology 0.62 ND
Performance status 0.66 ND
Time to progression for 1st TKI therapy 0.09 0.06
Time to progression ≥18 months for 1st TKI therapy 0.01 0.008
Time to progression for all lines of chemotherapy treatment before 2nd TKI therapy 0.41 ND
Time interval between end of 1st TKI therapy and start of afatinib or erlotinib 0.40 ND
Time interval between end of last chemotherapy treatment and start of afatinib or erlotinib 0.88 ND
  1. Note: Only covariates found significant in univariate analysis (p < 0.1) were considered in multivariate analysis
  2. Abbreviations: ND not done, TKI tyrosine-kinase inhibitor